The MRFF investment includes grants for:
- Biologics for the prophylaxis and treatment of COVID-19
- Ovarian cancer: investing variations in care and survival, aetiology and risk factors to improve outcomes in Australia via national data linkage
- A randomised control trial of positive end-expiratory pressure levels during resuscitation of preterm infants at birth.
More than 90% of the grants and three quarters of the funding awarded to date have been through competitive funding rounds.
“This shows the MRFF is investing in the highest quality research and I applaud the Government for building competitive and robust funding structures,” said AAMRI President, Professor Jonathan Carapetis AM.
“It is great to see this new investment in medical research, the scale of which is unprecedented and will in turn deliver huge economic and health benefits for the nation.
“The value and trust that the Government has placed on research will enable some of our best and brightest minds to make life-changing medical discoveries which will help protect and save lives.
“I’m also very pleased to see the rapid investment in COVID-19 and bushfire health research. This fits with the vision of the MRFF, to include an ability to respond quickly to emerging health threats,” Professor Carapetis.
The MRFF is a once-in-a-generation funding opportunity that will make Australia a world-leader in medical research. It will invest an additional $650 million per year in medical research, which is on top of the near $900 million invested through the NHMRC.